New antibody aims to unleash immune system against advanced tumors

NCT ID NCT03908814

Completed Disease control Sponsor: Dragonboat Biopharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called LDP, an antibody that blocks PD-L1, a protein cancers use to hide from the immune system. The study enrolls adults with advanced malignant tumors who have exhausted standard treatments. Researchers are evaluating the drug's safety, tolerability, and how the body processes it at different dose levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LDP (anti-PD-L1 antibody)
What this could lead to: If successful, this could lead to a new immunotherapy option for people with advanced cancers that have not responded to standard treatments.
What could go wrong: This is an early Phase 1 trial focused on safety and dosing, so it is not yet known if LDP will effectively shrink tumors. Side effects, including immune-related reactions, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TUMORS

Contacts and locations

Show contact details

Locations

Dragonboat Biopharmaceutical,Co.,Ltd

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.